ReviewThe Journal of antimicrobial chemotherapy2018
What has changed in the treatment of invasive candidiasis? A look at the past 10 years and ahead.
Review in The Journal of antimicrobial chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 96 citations in OpenAlex.
- Epidemiology, antifungal susceptibility, risk factors, and mortality of adult candidemia at a tertiary hospital in Eastern China from 2020 to 2025.BMC infectious diseases · 2026Article
- Construction and validation of a predictive nomogram model for invasive fungal infections in sepsis patients with severe pneumonia in the ICU.Frontiers in cellular and infection microbiology · 2026Article
- Diagnostic Potential of a Recombinant Candida albicans Hyr1 Protein.Mycopathologia · 2025Article
- Candidemia in a General Hospital in Kuwait: Epidemiology, Species Distribution, Risk Factors, and Antifungal Susceptibility Patterns over a 10-Year Period (2015-2024).Journal of fungi (Basel, Switzerland) · 2025Article
- It's Here, It's There, There's Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis.Infectious diseases and therapy · 2025Article
- In vitro long-term exposure to chlorhexidine or triclosan induces cross-resistance against azoles in Nakaseomyces glabratus.Antimicrobial resistance and infection control · 2025Article
- Antifungal and anti-biofilm effects of hydrazone derivatives onJournal of enzyme inhibition and medicinal chemistry · 2024Article
- A Cluster of Diutina catenulata Funguria in Patients with Coronavirus Disease 2019 (COVID-19) Hospitalized in a Tertiary Reference Hospital from Rio de Janeiro, Brazil.Current microbiology · 2024Article
- Article
- Discovery of a new chemical scaffold for the treatment of superbugEmerging microbes & infections · 2023Article
- Structural and Functional Alterations Caused by Aureobasidin A in Clinical Resistant Strains ofJournal of fungi (Basel, Switzerland) · 2023Article
- A study of the association between virulence factors and antifungal susceptibility profile ofJournal of family medicine and primary care · 2023Article
- Continuing Shifts in Epidemiology and Antifungal Susceptibility Highlight the Need for Improved Disease Management of Invasive Candidiasis.Microorganisms · 2022Review
- Mortality-associated factors of candidemia: a multi-center prospective cohort in Turkey.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Observational
- Prediction of Prognostic Risk Factors in Patients with Invasive Candidiasis and Cancer: A Single-Centre Retrospective Study.BioMed research international · 2022Article
- Advances in anti-fungal therapies.Mycopathologia · 2021Review
- Lessons from an Educational Invasive Fungal Disease Conference on Hospital Antifungal Stewardship Practices across the UK and Ireland.Journal of fungi (Basel, Switzerland) · 2021Review
- Blood Stream Infections from MDR Bacteria.Life (Basel, Switzerland) · 2021Review
- Different characteristics of bloodstream infection during venoarterial and venovenous extracorporeal membrane oxygenation in adult patients.Scientific reports · 2021Article
- Renal CD169Life science alliance · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 3 countries.
Funding
Abstract
The treatment of invasive candidiasis has changed greatly in the past decade and must continue to evolve if we are to improve outcomes in this serious infection. A review of recent history may provide insights for the future. The morbidity and mortality of invasive candidiasis remain difficult to measure despite an obvious clinical burden. Current treatment guidelines now recommend echinocandins as first-line empirical treatment, with fluconazole as an acceptable alternative for selected patients, reflecting the efficacy demonstrated by echinocandins and increasing resistance observed with fluconazole. The selection of antifungal therapy now must consider not only resistance but also the shift in predominance from Candida albicans to non-albicans species, notably Candida glabrata. The recent emergence of Candida auris has been met with great interest, although the longer-term implications of this phenomenon remain unclear. The broad goal of treatment continues to be administration of safe, efficacious antifungal therapy as soon as possible. Diagnostic methods beyond traditional blood culture present an opportunity to shorten the time to an accurate diagnosis, and earlier treatment initiation based on prophylactic and empirical or pre-emptive strategies seeks to ensure timely therapeutic intervention. In addition, there are novel agents in the antifungal pipeline. These developments, as well as ongoing studies of dosing, toxicity and resistance development, are important items on the current research agenda and may play a role in future changes to the treatment of invasive candidiasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.